ARCPF (ARCpoint) 3-Year RORE % : -72.73% (As of Dec. 2025)


What is ARCpoint 3-Year RORE %?

ARCpoint ARCPF -56.33% 3-Year RORE % is -72.73 as of Dec. 2025. The stock has 6 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, ARCpoint ranks worse than 88.61% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. ARCpoint's 3-Year RORE % for the quarter that ended in Dec. 2025 was -72.73%.

The industry rank for ARCpoint's 3-Year RORE % or its related term are showing as below:

ARCPF's 3-Year RORE % is ranked worse than
88.61% of 202 companies
in the Medical Diagnostics & Research industry
Industry Median: -7.935 vs ARCPF: -72.73

ARCpoint  (OTCPK:ARCPF) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


ARCpoint 3-Year RORE % Related Terms


ARCpoint 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for ARCpoint's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ARCpoint 3-Year RORE % Chart

ARCpoint Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
3-Year RORE %
Get a 7-Day Free Trial 0.00 0.00 117.16 -55.80 -72.73

ARCpoint Quarterly Data
Dec20 Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -55.80 -69.85 -79.70 -60.45 -72.73

ARCPF vs TMO, DHR, IDXX: 3-Year RORE % Comparison

For the Diagnostics & Research subindustry, ARCpoint's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ARCpoint 3-Year RORE % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, ARCpoint's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where ARCpoint's 3-Year RORE % falls into.



ARCpoint 3-Year RORE % Calculation

ARCpoint's 3-Year RORE % for the quarter that ended in Dec. 2025 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -0.02--0.1 )/( -0.11-0 )
=0.08/-0.11
=-72.73 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of -72.73 mean?
ARCpoint (ARCPF) has a 3-Year RORE % of -72.73 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on ARCpoint and its competitors. According to the industry distribution chart, ARCpoint ranks #179 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 88.6%.
Is ARCpoint's 3-Year RORE % too high?
ARCpoint's current 3-Year RORE % is -72.73. Based on the distribution chart, ARCpoint ranks #179 out of 202 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does ARCpoint's 3-Year RORE % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, ARCpoint ranks #179 out of 202 companies for 3-Year RORE %. This places ARCpoint in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Diagnostics & Research company?
A good 3-Year RORE % depends on the Medical Diagnostics & Research industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on ARCpoint and its competitors. ARCpoint's current 3-Year RORE % is -72.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ARCpoint stock overvalued right now?
Based on GuruFocus' analysis, ARCpoint (ARCPF) is currently considered Fairly Valued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading right at its estimated fair value. The current 3-Year RORE % is -72.73. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For ARCpoint (ARCPF), the current 3-Year RORE % is -72.73 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ARCpoint Business Description

Other Exchanges ARC:Canada
Address 101 North Main Street, Suite 301, Greenville, SC, USA, 29601
ARCpoint Inc is a U.S-based franchise system providing drug testing, alcohol screening, DNA and clinical lab testing, corporate wellness programs, and employment and background screening, among other services. The platform also digitalizes and streamlines administrative functions such as materials purchasing, compliance, billing, and physician services for ARCpoint franchise labs and other clients.